XYZ Pharmaceuticals reported a strong Q2 2023, with revenues reaching $2.8 billion, up 15% from the previous year.
The company's flagship drug, Cardiolex, contributed $500 million to the total sales.
Dr. Emily Chen, the newly appointed CFO, stated that the company plans to invest $150 million in R&D over the next fiscal year.
XYZ's stock (NASDAQ: XYZP) closed at $78.50, up 3.2% following the announcement.